Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients.

Slides:



Advertisements
Similar presentations
Evaluating cell lines as tumor models by comparison of genomic profiles Domcke, S. et al. Nat. Commun 4:2126.
Advertisements

PD-L1 Expression in Metastatic Cutaneous Squamous Cell Carcinomas Nathaniel A. Slater, MD1, James Tidwell, MD2, George Sonnier, MD2, Paul Googe, MD1,3.
A B C ErbB3 protein levels ERBB3 mRNA levels P = P = 0.716
The cBio Cancer Genomics Portal.
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Fig. 4. Primary human metastatic melanomas contain CCL21-expressing LECs, and expression of VEGFC positively correlates with hallmarks of tumor inflammation.
Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.
Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.
WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.
Altered interferon signaling with JAK1 loss-of-function mutation in M431 and interferon gamma-inducible PD-L1 expression by 48 melanoma cell lines. Altered.
Genomic alterations in breast cancer cell line MDA-MB-231.
Intrinsic and acquired trastuzumab resistance.
Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.
Volume 5, Issue 4, Pages e5 (October 2017)
Volume 165, Issue 1, Pages (March 2016)
CHK1 downregulation upon ERG overexpression.
PD-1 expression on HCC-infiltrating B cells and its clinical significance. PD-1 expression on HCC-infiltrating B cells and its clinical significance. A–H,
Schematic model of effector pathways that mediate tumor suppression by p53. Schematic model of effector pathways that mediate tumor suppression by p53.
Bar plot representation of the transcriptomic changes in Δsaci_ptp and Δsaci_pp2a. Bar plot representation of the transcriptomic changes in Δsaci_ptp and.
Existence of a nuclear NFATc1–STAT3 complex in pancreatic cancer.
LATS2-associated gene expression pattern is down-regulated specifically in lumB breast tumors. LATS2-associated gene expression pattern is down-regulated.
Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.
FAK overexpression in invasive human breast cancer and DCIS
A, PTEN loss signature score in resected SQCLC brain metastases.
Oncogenic indel hotspots.
KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,
CHCHD2 and EGFR protein expression in NSCLC
Western blot analysis of Wnt signaling genes.
M-Wnt and E-Wnt cells cluster tightly with claudin-low and basal-like breast tumors, respectively, by microarray analysis. M-Wnt and E-Wnt cells cluster.
Melanoma patient monocytes have altered expression of inflammatory and surface markers. Melanoma patient monocytes have altered expression of inflammatory.
EN1 expression in breast cancer and clinical outcome.
PTEN expression regulates autophagy in tumor cells, reducing T cell–mediated killing. PTEN expression regulates autophagy in tumor cells, reducing T cell–mediated.
Targetable alterations and pathways in TNBCs after NAC
CREBBP loss-of-function results in gene expression repression signature. CREBBP loss-of-function results in gene expression repression signature. A–D,
Bortezomib induces an NRF2 signature and NRF2 protein in tumor cells from leukemic MCL. Gene sets regulated by bortezomib (Supplementary Tables S3 and.
PD-L1 is expressed in breast cancer.
Tivantinib does not inhibit MET function.
Location of the ER mutations and frequencies per cohort.
Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.
Frequently mutated genes in colorectal cancer.
Molecular definitions of lung adenocarcinoma subtypes.
Putative molecular pathways showing how GSK3β regulates the fate of tumor cells (survival, proliferation, or apoptosis) and influences their sensitivity.
Western blotting confirming the presence of fusion proteins in tumor lysates and showing increased signaling pathway activation in respective tumors. Western.
The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.
Reduced expression of the tumor suppressor PTEN occurs in tumors with both squamous cell and adenocarcinoma histology. Reduced expression of the tumor.
Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.
Identification of RASA1- and NF1-mutated lung cancer cell lines in the CCLE dataset (accessed via the cBioPortal for Cancer Genomics at
Defining the eTME genes.
Phosphorylation of Twist1 in human breast cancer cell lines and tumors
Germline variants influencing primary tumor type.
A, heatmap of copy number alterations determined by array CGH for a panel of 79 frozen NSCLC samples. A, heatmap of copy number alterations determined.
In vivo shRNA screening in PDXs from 3 patients with melanoma.
Correlations between APOBEC expression and immune cell markers across 22 cancer types. Correlations between APOBEC expression and immune cell markers across.
Global analysis of the chemical–genetic interaction map.
Mutational signature analysis of WES data from patients with advanced PDAC. A, Projection of signatures representing four main mutational processes identified.
Collin Tokheim, Rachel Karchin  Cell Systems 
Gene expression heatmap of non–T-cell-inflamed, intermediate, and T-cell–inflamed testicular germ cell tumors from TCGA. Genes are on the row, and samples.
PTEN genotype frequently dictates PTEN expression status, but evidence of heterogeneous staining implies polyclonality within some ovarian tumors. PTEN.
The ovarian cancer cell lines modestly recapitulate the spectrum of mutations found in primary ovarian tumors. The ovarian cancer cell lines modestly recapitulate.
High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.
Driver pathways and key genes in OSCC
CASP8 mutations are associated with fewer CNAs and RAS family mutations. CASP8 mutations are associated with fewer CNAs and RAS family mutations. A, number.
Integrated analysis of gene expression and copy number alterations.
Highly metastatic PDAC cells have a unique gene signature, which is not preserved in metastases but predicts poor patient outcome. Highly metastatic PDAC.
Genomic instability is a core feature of ovarian cancer that frequently involves DNA-damage repair genes. Genomic instability is a core feature of ovarian.
Genomic and proteomic profiling of ovarian cancer cell lines.
Synthetic lethality of ROS1 inhibition in E-cadherin–deficient breast tumor cell lines. Synthetic lethality of ROS1 inhibition in E-cadherin–deficient.
PD-L1 expression is not associated with PTEN expression status in melanomas. PD-L1 expression is not associated with PTEN expression status in melanomas.
ENTPD5 expression correlates with EGFR and activated AKT levels in human NSCLC. A, percentages of PTEN-low lung adenocarcinoma cases with at least one.
Increased blood–CSF barrier permeability during neurotoxicity (NTX).
Presentation transcript:

Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients whose information was included in TCGA were stratified based on the PTEN CN (cutoff, ≤−0.4, which was chos... Reduced number and impaired effector functions of TILs in tumors with PTEN deletion or loss-of-function mutations in PTEN. Cutaneous melanoma patients whose information was included in TCGA were stratified based on the PTEN CN (cutoff, ≤−0.4, which was chosen in order to maximize the difference in the level of activity of the AKT pathway). A box-and-whisker plot was used to demonstrate the differences in expression levels of indicated genes or proteins between these two groups. A, comparison of the intensity of phosphorylated AKT and LCK in melanomas obtained from patients with different PTEN CNs according to RPPA. B, the mRNA expression levels for genes encoding IFNγ and granzyme B in tumor samples obtained from melanoma patients with different PTEN CNs. C, comparison of lymphocytic infiltration score (Lscore), as determined by pathological review, between groups of patients with different PTEN CNs. The P values of the comparisons were determined by unpaired t test. D, frequencies of genetic alterations in the β-catenin pathway and PTEN between T cell–inflamed and non-T cell–inflamed tumors. Metastatic melanomas from TCGA were first catalogued based on T-cell infiltration and subsequently based on activating mutations in β-catenin itself (CTNNB1) or loss-of-function (LOF) mutations in negative regulators of the β-catenin pathway (APC, APC2, AXIN1, and AXIN2), and PTEN deletion or PTEN mutations. Non-T cell–inflamed tumors have an increased frequency of PTEN alterations compared to the T cell–inflamed tumors (P < 0.01 by Fisher exact test). Weiyi Peng et al. Cancer Discov 2016;6:202-216 ©2016 by American Association for Cancer Research